Terapia antiandrogénica como quimioprevención del cáncer de próstata

Article information

La deprivación hormonal que producen los inhibidores de la 5-alfa-reductasa sobre el tejido prostático ha sugerido la posibilidad de que agentes tales como el finasteride puedan desempeñar algún papel en la prevención del cáncer prostático.

En el presente artículo se presenta un caso de neoplasia intraepitelial prostática, tratado por su hiperplasia prostática benigna acompañante con finasteride, que evolucionó a atrofia prostática biopsiada. Se discute el mecanismo de acción de este tipo de terapia antiandrogénica en estas displasias y se revisa la literatura actual sobre su posible efecto en la reducción del riesgo de cáncer de próstata.

Palabras clave:

cáncer de próstata

prevención

finasteride

Hormonal deprivation produced by the 5-alpha-reductase inhibitors on the prostatic tissue has suggested the possibility that agents such as finasteride may play some role in the prevention of prostate cancer.

The present article presents a case of prostatic interepithelial neoplasm (PIN) treated for its accompanying benign prostatic hyperplasia with finasteride, that evolved to biopsied prostatic atrophy. The action mechanism of this type of anti-androgenic therapy in these dysplasias is discussed and the prevent literature on its possible effect in the reduction of the risk of prostate cancer is reviewed.

Key words:

prostate cancer

prevention

finasteride

Full text is only aviable in PDF

Bibliografía

[1.]

T.M. Seay, I.M. Thompson.

Screening for carcinoma of the prostate. Progress and problems.

Cancer of the prostate, pp. 119-146

[2.]

R. Liebermen.

Androgen deprivation therapy for prostate cancer chemoprevention: Current status and future directions for agent development.

Urology, 58 (2001), pp. 83-90

Medline

[3.]

S.A. Kaplan.

5 alpha-reductase inhibitors: What role should they play?.

Urology, 58 (2001), pp. 65-70

Medline

[4.]

R.J. Cote, E.C. Skinner, C.E. Salem, et al.

The effect of finasteride on the prostate gland in men with elevated serum prostate-specific antigen levels.

Br J Cancer, 78 (1998), pp. 413-418

Medline

[5.]

X.J. Yang, K. Lecksell, K. Short, et al.

Does long-term finasteride therapy affect the histologic features of benign prostatic tissue and prostate cancer on needle biopsy?.

Urology, 53 (1999), pp. 696-700

Medline

[6.]

D.G. Bostwick, J.Q. Qian.

Effect of androgen deprivation therapy on prostatic intraepithelial neoplasia.

Urology, 58 (2001), pp. 91-93

Medline

[7.]

P.S. Nelson, T.P. Gleason, M.K. Brawer, et al.

Chemoprevention for prostatic intraepithelial neoplasia.

Eur Urology, 30 (1996), pp. 269-278

[8.]

M. Bologna, C. Vicentini, C. Festuccia, et al.

Inhibition of invasive capacity of prostatic carcinoma primary cultures by finasteride.

Eur Urol, 35 (1999), pp. 76

[9.]

J.W. Aquilina, J.J. Lipsky, D.G. Bostwick.

Androgen deprivation as a strategy for prostate cancer chemoprevention.

J Natl Cancer Inst, 89 (1997), pp. 689-696

Medline

[10.]

C.G. Roehrborn, J. McConnell, J. Bonilla, et al.

Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. Proscar long-term efficacy and safety study.

J Urol, 163 (2000), pp. 13-20

Medline

[11.]

P. Feigl, B. Blumenstein, I.M. Thompson, et al.

Design of the prostate cancer prevention trial (PCPT).

Controlled Clin Trials, 16 (1995), pp. 150-163

Medline

[12.]

I.M. Thompson, P.h.J. Goodman, C.M. Tangen, et al.

Influence of finasteride in the development of prostatic cancer.

N Engl J Med, 349 (2003), pp. 215-224

http://dx.doi.org/10.1056/NEJMoa030660 | Medline